NCT04510415 is a Phase 1 clinical trial of Olmutinib in Non Small Cell Lung Cancer, sponsored by Hanmi Pharmaceutical Company Limited.

Who is sponsoring NCT04510415?

NCT04510415 is sponsored by Hanmi Pharmaceutical Company Limited.

What drugs are being tested in NCT04510415?

Interventions in NCT04510415: Olmutinib.

What condition does NCT04510415 study?

NCT04510415 studies Non Small Cell Lung Cancer.

Is NCT04510415 still recruiting?

NCT04510415 is currently terminated. Last updated 12 August 2020.

Last reviewed 2020-08-12 · How we verify

NCT04510415

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI

Terminated Phase 1 Last updated 12 August 2020

What this trial tests

Phase 1 trial testing Olmutinib in Non Small Cell Lung Cancer in 2 participants. Terminated before completion.

Timeline

29 March 2018

Primary endpoint
11 December 2018

11 December 2018

Quick facts

Lead sponsor	Hanmi Pharmaceutical Company Limited
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	29 March 2018
Primary completion	11 December 2018
Estimated completion	11 December 2018
Sites	8 locations across South Korea

Drugs / interventions tested

Olmutinib — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

Hanmi Pharmaceutical Company Limited — full company profile →

Who can join

20 and older, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of olmutinib 600 mg QD in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Tyrosine Kinase Receptors in Oncology.
Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Román-Gil M, et al · · 2020 · cited 72× · PMID 33198314 · DOI 10.3390/ijms21228529
New small molecules in dermatology: for the autoimmunity, inflammation and beyond.
Criado PR, Lorenzini D, Miot HA, Bueno-Filho R, et al · · 2023 · cited 4× · PMID 37212867 · DOI 10.1007/s00011-023-01744-w

Verify or expand the search:

Other trials of Olmutinib

Trials testing the same drug.

NCT03228277 — Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA · Phase 2 · completed

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Hanmi Pharmaceutical Company Limited trials

Trials by the same sponsor.

NCT07297693 — A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers · Phase 1 · not yet recruiting
NCT06595004 — A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients · Phase 3 · completed
NCT06518122 — A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers · Phase 1 · completed
NCT06481098 — A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects. · Phase 1 · completed
NCT06357910 — A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy V · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04510415 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hanmi Pharmaceutical Company Limited
Last refreshed: 12 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04510415.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing